MedTrace Logo

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

NCT03922204 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-12-11

No results posted yet for this study

Summary

This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas. The study will be conducted in 2 parts.

Conditions

Interventions

DRUG

MCLA-145

full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137

DRUG

Pembrolizumab (Keytruda)

Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W.

Sponsors & Collaborators

  • Merus N.V.

    lead INDUSTRY

Principal Investigators

  • Gianluca Laus, MD · Merus N.V.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-08
Primary Completion
2024-11-07
Completion
2024-11-07
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03922204 on ClinicalTrials.gov